These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21106864)

  • 1. Defining and achieving treatment success in patients with type 2 diabetes mellitus.
    Stolar MW
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S50-9. PubMed ID: 21106864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
    Davidson JA
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S27-37. PubMed ID: 21106865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus.
    Unger J
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S38-49. PubMed ID: 21106866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.
    Freeman JS
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S5-S14. PubMed ID: 21106868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
    Garber AJ
    J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S20-30. PubMed ID: 21813733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J; Nadeau DA
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
    Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
    J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia.
    Schwartz SS; Kohl BA
    Mayo Clin Proc; 2010 Dec; 85(12 Suppl):S15-26. PubMed ID: 21106867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure-lowering effects of incretin-based diabetes therapies.
    Lovshin JA; Zinman B
    Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.
    Wilding JP; Rajeev SP; DeFronzo RA
    Diabetes Care; 2016 Aug; 39 Suppl 2():S154-64. PubMed ID: 27440828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus.
    Tibaldi J
    Am J Med Sci; 2014 Jun; 347(6):491-501. PubMed ID: 24469234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
    Dedov II; Shestakova MV; Sukhareva OIu
    Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S
    Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin therapy for type 2 diabetes mellitus.
    Klonoff DC
    Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
    Carramiñana Barrera FC
    Semergen; 2018 Jun; 44 Suppl 1():10-17. PubMed ID: 30322468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.